MARKET

ALKS

ALKS

Alkermes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.69
-0.35
-1.75%
Closed 16:12 07/10 EDT
OPEN
19.98
PREV CLOSE
20.04
HIGH
20.25
LOW
19.47
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
25.35
52 WEEK LOW
11.98
MARKET CAP
3.13B
P/E (TTM)
-22.3167
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 13 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALKS stock price target is 19.09 with a high estimate of 26.00 and a low estimate of 16.00.

EPS

ALKS News

More
Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?
Zacks · 06/30 14:36
Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program
PR Newswire · 06/29 12:00
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
Alkermes plc (Nasdaq: ALKS) today announced that 10 nonprofit organizations have been awarded grants from the company's COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program, that was established to assist nonp
PR Newswire · 06/24 11:00
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
PR Newswire · 06/22 14:01
Alkermes Highlights New Preclinical Data On ALKS 4230 In Combo With Lucitanib Presented At AACR
 Alkermes plc (NASDAQ:ALKS) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes'
Benzinga · 06/22 13:19
Alzheimer's Drug Approval More Critical for Biogen After Patent Decision
GuruFocus.com · 06/19 23:04
Edited Transcript of ALKS earnings conference call or presentation 29-Apr-20 12:00pm GMT
Thomson Reuters StreetEvents · 06/16 12:28
Should You Avoid Alkermes Plc (ALKS)?
Insider Monkey · 06/12 14:11

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ALKS

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
More

Webull offers kinds of Alkermes Plc stock information, including NASDAQ:ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.